Altor Sells PaloDEx to Danaher

Altor, a leading Nordic buy-out fund, today announced that it has signed a definitive agreement to sell PaloDEx to Danaher Corporation. Altor acquired the dental imaging assets from GE as a carve-out of non-core assets in September 2005 and formed a leading dental imaging company named PaloDEx. Jaakko Kivinen, Partner of Altor Equity Partners, commented: “During Altor’s ownership, the objective has been to establish an independent company that can accelerate growth and improve operational efficiency of the dental imaging assets that were non-core operations for GE. As a result of the hard work of the management team and consistent execution of the operational agenda, PaloDEx has grown faster than the market with increasing profitability and improved working capital efficiency during our ownership.” “To help achieve these results, we recruited a high quality, internationally experienced board and management team with strong leadership to execute on the ambitious operational plan, in line with Altor’s investment strategy of building lasting value in partnership with management. We are delighted that PaloDEx’s management team, led by Henrik Roos and Jyrki Perttunen, have delivered on that plan. This has been a very successful investment for us.” “During our ownership, PaloDEx accelerated the pace of its product launches with several attractive and innovative products and revitalized the customer service driven strategy”, comments Fredrik Strömholm, Partner of Altor Equity Partners. “There is strong industrial logic behind the acquisition by Danaher, as a leading dental company in the world seeking to strengthen their dental imaging operations. The development of PaloDEx under Altor’s ownership is evidence of Altor’s capability of building non-core operations into attractive, globally leading companies in their field.” “The transaction further contributes to PaloDEx’s strengths. We believe Danaher will be a great owner for PaloDEx, and as a key part of Danaher’s Dental Platform, PaloDEx will be able to expand its potential in the increasingly dynamic dental industry”, comments Henrik Roos, CEO of PaloDEx.

Tags:

About Us

Since inception, the family of Altor funds has raised some EUR 5.8 billion in total commitments. The funds have invested in excess of EUR 3.4 billion in more than 40 companies. The investments have been made in medium sized Nordic companies with the aim to create value through growth initiatives and operational improvements. Among current and past investments are Rossignol, Spectrum, Apotek Hjärtat, Hamlet Protein, Carnegie, Helly Hansen, Dustin and Byggmax. For more information visit www.altor.com.

Subscribe

Documents & Links